Yao Y, Jin L, Fuchs A, Joseph A, Hastings H M, Goldberg I D, Rosen E M
Department of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.
Am J Pathol. 1996 Nov;149(5):1707-17.
Scatter factor (SF) is an invasogenic and angiogenic cytokine the cellular receptor of which is encoded by a proto-oncogene (c-met). We measured the immunoreactive SF content (nanograms of SF per milligram of protein) in tissue extracts from 166 breast cancers and correlated the values with various known prognostic parameters. Invasive cancers had nearly four times greater SF content than did ductal carcinoma in situ, and the difference was statistically significant (P < 0.02, two-tailed t-test). However, there were no significant differences in SF content among different histological types of invasive cancer. Invasive cancers that had spread to axillary lymph nodes exhibited higher SF content than did invasive cancers without regional spread (P < 0.02), but the difference in SF content between node-positive and node-negative tumors was not as great as that between invasive and ductal carcinoma in situ tumors. There was a trend toward increased SF content in larger primary tumors as compared with smaller tumors, but statistical comparison revealed borderline significance (0.05 < P < 1.0). There was no significant correlation between SF content and other parameters, including estrogen receptor, progesterone receptor, DNA ploidy, S phase, or Scarff-Bloom-Richardson score. We also measured the content of von Willebrand factor (a marker of blood vessels) and interleukin-1 beta (a pro-inflammatory cytokine) in the same tumor extracts. SF content showed a strong positive correlation with von Willebrand factor content (P < 0.001) but did not appear to be correlated with interleukin-1 beta. These findings suggest that SF is correlated with several other clinicopathological indicators of aggressive tumor behavior, consistent with the hypothesis that SF is a biological factor that may play a role in breast cancer pathogenesis.
散射因子(SF)是一种具有侵袭性和促血管生成作用的细胞因子,其细胞受体由原癌基因(c-met)编码。我们测定了166例乳腺癌组织提取物中的免疫反应性SF含量(每毫克蛋白质中SF的纳克数),并将这些值与各种已知的预后参数进行了关联分析。浸润性癌的SF含量几乎是原位导管癌的四倍,差异具有统计学意义(P < 0.02,双侧t检验)。然而,不同组织学类型的浸润性癌之间的SF含量没有显著差异。已扩散至腋窝淋巴结的浸润性癌的SF含量高于无区域扩散的浸润性癌(P < 0.02),但淋巴结阳性和阴性肿瘤之间的SF含量差异不如浸润性癌与原位导管癌之间的差异大。与较小的原发性肿瘤相比,较大的原发性肿瘤有SF含量增加的趋势,但统计学比较显示临界显著性(0.05 < P < 1.0)。SF含量与其他参数之间无显著相关性,包括雌激素受体、孕激素受体、DNA倍体、S期或斯卡夫-布卢姆-理查森评分。我们还在相同的肿瘤提取物中测量了血管性血友病因子(一种血管标志物)和白细胞介素-1β(一种促炎细胞因子)的含量。SF含量与血管性血友病因子含量呈强正相关(P < 0.001),但似乎与白细胞介素-1β无关。这些发现表明,SF与侵袭性肿瘤行为的其他几个临床病理指标相关,这与SF是一种可能在乳腺癌发病机制中起作用的生物学因子的假设一致。